A RARE CLINICAL PRESENTATION: A PATIENT WITH CHRONIC RENAL FAILURE, SECONDARY HYPERPARATHYROIDISM AND CALCIPHYLAXIS.

Calciphylaxis, also known as calcific uremic arteriolopathy (CUA), is usually observed in women and it is a serious complication of hyperparathyroidism secondary to chronic renal failure. CUA is characterized by ischemic tissue loss secondary to progressive vascular degeneration. Although it is rare, it may end up with sepsis and organ failure and can be fatal. Its pathogenesis is not fully understood, but it is thought that it occurs secondary to increased calcification activators such as oxidized LDL, TNF- α, calcitriol, fibronectin, collagen-I, and TGF-1α. The most effective treatment is managing underlying pathology and decreasing serum calcium and phosphorus levels. In this report, we aimed to present an end stage renal failure case with coexisting hyperparathyroidism, hyperthyroidism and calciphylaxis in whom cutaneous manifestations were healed 6 months after parathyroidectomy.

[1]  O. Lupi,et al.  Cutaneous manifestations in end-stage renal disease. , 2011, Anais brasileiros de dermatologia.

[2]  M. Ketteler,et al.  Calciphylaxis: a still unmet challenge. , 2011, Journal of nephrology.

[3]  A. Bailey,et al.  Calciphylaxis: a review. , 2010, Plastic surgical nursing : official journal of the American Society of Plastic and Reconstructive Surgical Nurses.

[4]  R. Weigel,et al.  Determinants of survival in patients with calciphylaxis: a multivariate analysis. , 2009, Surgery.

[5]  R. Weenig.  Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B. , 2008, Journal of the American Academy of Dermatology.

[6]  Kazuhide Inoue,et al.  Thyroid Hormone Targets Matrix Gla Protein Gene Associated With Vascular Smooth Muscle Calcification , 2005, Circulation research.

[7]  R. Beissner,et al.  Calciphylaxis: Medical and Surgical Management of Chronic Extensive Wounds in a Renal Dialysis Population , 2004, Plastic and reconstructive surgery.

[8]  R. Crawford,et al.  Three-dimensional analysis of a calciphylaxis plaque: clues to pathogenesis. , 2002, Journal of the American Academy of Dermatology.

[9]  C. Magro,et al.  Calciphylaxis: Emerging Concepts in Prevention, Diagnosis, and Treatment , 2002, Seminars in dialysis.

[10]  A. Fine,et al.  Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. , 2002, Kidney international.

[11]  Herb Chen,et al.  Parathyroidectomy promotes wound healing and prolongs survival in patients with calciphylaxis from secondary hyperparathyroidism. , 2001, Surgery.

[12]  C. Stehman-Breen,et al.  Risk factors and mortality associated with calciphylaxis in end-stage renal disease. , 2001, Kidney international.

[13]  A. Evan,et al.  Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  S. Myers,et al.  Calciphylaxis in patients on hemodialysis: a prevalence study. , 1997, Surgery.

[15]  H. Selye.  The dermatologic implications of stress and calciphylaxis. , 1962, The Journal of investigative dermatology.

[16]  H. Selye,et al.  Sensitization to calciphylaxis by endogenous parathyroid hormone. , 1962, Endocrinology.